반응식
[CH2:1]([N:3]1[CH:7]=[C:6](B2OC(C)(C)C(C)(C)O2)[CH:5]=[N:4]1)[CH3:2].[NH2:17][CH:18]1[CH2:24][CH2:23][CH2:22][CH2:21][N:20](C(OC(C)(C)C)=O)[CH2:19]1>>[CH2:1]([N:3]1[CH:7]=[C:6]([C:21]2[N:20]=[CH:19][C:6]3[CH:5]=[N:4][N:3]([C:1]4[N:17]=[C:18]([NH:17][CH:18]5[CH2:24][CH2:23][CH2:22][CH2:21][NH:20][CH2:19]5)[CH:24]=[CH:23][CH:2]=4)[C:7]=3[CH:22]=2)[CH:5]=[N:4]1)[CH3:2]참가 물질
3
실험 절차
Following the procedures as described in EXAMPLE 8 and starting with 1-ethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole and tert-butyl 3-aminoazepane-1-carboxylate, 143 was obtained as an off-white solid (3.6 mg, 2.8%) over 2 steps. MS (ESI) m/z: 403.2 [M+H]+
출처 및 근거
- ORD 기록
- ord-dbdd60ba933d40efa4e90715a30d0c9e
- 출처 데이터셋
- uspto-grants-2016_09
- 특허 번호
- US09434725B2
연결된 노트
불러오는 중…